Skip to content

Author

Yu-Qin Cao

We have 3 of 50 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Upfront surgery versus neoadjuvant chemoimmunotherapy versus neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma in elderly patients: a multicenter cohort study

The optimal treatment strategy for elderly patients (aged ≥65 years) with operable locally advanced esophageal squamous cell carcinoma (ESCC) remains controversial. This study aimed to compare the survival outcomes of upfront surgery (US), neoadjuvant chemoimmunotherapy (nCIT), and neoadjuvant chemoradiotherapy (nC...

Z. Hou, Yi-Xiang Zhu, M. Lan et al. · 0 citations
Open access Aug 2026

PD09.07. Impact of Type 2 Diabetes on Outcomes of Neoadjuvant Therapy and Surgery for Esophageal Cancer: A Multi-Center Retrospective Study

Type 2 diabetes was not associated with increased perioperative morbidity or impaired long-term survival following neoadjuvant therapy and surgery following esophageal cancer patients receiving neoadjuvant therapy and surgery.

Xi-Peng Wang, Zhi-Chao Liu, Xue-Feng Leng et al. · 0 citations
Aug 2026

P1.086. Impact of Surgery Versus Non-Surgery on the Prognosis of Esophageal Cancer Patients With Clinically Identified Metastatic Supraclavicular Lymph Nodes

Surgical resection may offer a survival benefit for patients with esophageal cancer and SCLN metastases, supporting its role in specific cases, and tumor location should be recognized as a determinant in therapeutic decision.

Yi-Heng Huang, Yu-Qin Cao, He-Cheng Li · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.